Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Nizoral AD

This article was originally published in The Tan Sheet

Executive Summary

Nizoral AD: Three years of Waxman/Hatch market exclusivity for Johnson & Johnson's ketoconozole 1% antidandruff shampoo granted until Oct. 10, 2000, according to a recent update to FDA's Orange Book. The exclusivity award is based on the clinical trials submitted in the NDA considered by the agency to be essential to the approval, according to FDA documents. The approval of the switch product involved a concurrent change to the indication of the company's prescription ketoconazole (2%) shampoo ("The Tan Sheet" Oct. 20, 1997, p. 3). J&J Consumer Products has not announced marketing plans for Nizoral AD...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel